The Effect of Enalapril, Losartan or Not Antihypertensive on the Oxidative Status in Renal Transplant Recipients

An open, randomized clinical trial is proposed with a control group. It is carried out in the Transplant Division of the High Specialty Medical Unit of the Hospital de Especialidades, Centro Médico Nacional de Occidente of the Mexican Institute of Social Security in Guadalajara, Jalisco, Mexico. The sample size was based on the formula to evaluate mean differences for clinical trials. Three study groups were formed; thirteen patients with RT who did not require any antihypertensive. Thirteen RT patients to receive Enalapril as an antihypertensive regimen. Thirteen RT patients to receive Losartan as an antihypertensive regimen in the post-transplant period. Recipients of a RT, from a living related donor (DVR) or living unrelated donor (DVNoR) who agreed to participate and signed the Letter of Consent under Information.

Patients who received an RT from a deceased donor, from a donor >55 years, with renal comorbidities at the time of the study (urolithiasis, infections, diabetes), with blood dyscrasias, second transplantation, treatment with non-steroidal anti-inflammatory drugs, statins, spironolactone, pentoxifylline, patients with neurodegenerative processes or who withdrew the Letter of Consent under Information are not eligeble.

Inclusion criteria

• Renal trasplant, from a living related donor (DVR) or living unrelated donor (DVNoR)
• Who agreed to participate and signed the Letter of Consent under Information.

Exclusion criteria

• Patients who received an RT from a deceased donor,
• With donor >55 years,
• With renal comorbidities at the time of the study (urolithiasis, infections, diabetes),
• With blood dyscrasias,
• Second transplantation,
• Those with treatment with non-steroidal anti-inflammatory drugs,
• Treatment with statins, spironolactone, pentoxifylline, patients
• With neurodegenerative processes
• Those who withdrew the Letter of Consent under Information